Universidad de Extremadura-ko ikertzaileekin lankidetzan egindako argitalpenak (16)

2022

  1. Effectiveness of CPAP vs. Noninvasive Ventilation Based on Disease Severity in Obesity Hypoventilation Syndrome and Concomitant Severe Obstructive Sleep Apnea

    Archivos de Bronconeumologia, Vol. 58, Núm. 3, pp. 228-236

  2. Risk factors associated with pulmonary hypertension in obesity hypoventilation syndrome

    Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine, Vol. 18, Núm. 4, pp. 983-992

  3. Updates on the utility of anterior segment optical coherence tomography in the assessment of filtration blebs after glaucoma surgery

    Acta Ophthalmologica, Vol. 100, Núm. 1, pp. e29-e37

2020

  1. Cost-effectiveness of positive airway pressure modalities in obesity hypoventilation syndrome with severe obstructive sleep apnoea

    Thorax, Vol. 75, Núm. 6, pp. 459-467

  2. Echocardiographic changes with positive airway pressure therapy in obesity hypoventilation syndrome long-term pickwick randomized controlled clinical trial

    American Journal of Respiratory and Critical Care Medicine, Vol. 201, Núm. 5, pp. 586-597

  3. Eficacia y coste-efectividad del diagnóstico y decisión terapéutica de la apnea obstructiva del sueño en atención primaria: descripción de la metodología.

    Revista española de patología torácica, Vol. 32, Núm. 4, pp. 260-274

  4. Long-term Noninvasive Ventilation in Obesity Hypoventilation Syndrome Without Severe OSA: The Pickwick Randomized Controlled Trial

    Chest, Vol. 158, Núm. 3, pp. 1176-1186

2019

  1. Actualización de la utilidad de la tomografía de coherencia óptica para el estudio del ángulo iridocorneal

    Archivos de la Sociedad Española de Oftalmologia, Vol. 94, Núm. 10, pp. 478-490

  2. Long-term clinical effectiveness of continuous positive airway pressure therapy versus non-invasive ventilation therapy in patients with obesity hypoventilation syndrome: a multicentre, open-label, randomised controlled trial

    The Lancet, Vol. 393, Núm. 10182, pp. 1721-1732

2018

  1. Evolution of metabolic risk factors over a two-year period in a cohort of first episodes of psychosis

    Schizophrenia Research, Vol. 193, pp. 188-196

  2. Impact of NTRK2, DRD2 and ACE polymorphisms on prolactin levels in antipsychotic-treated patients with first-episode psychosis

    Journal of Psychopharmacology, Vol. 32, Núm. 6, pp. 702-710

  3. Primary care physicians can comprehensively manage patients with sleep apnea a noninferiority randomized controlled trial

    American Journal of Respiratory and Critical Care Medicine, Vol. 198, Núm. 5, pp. 648-656

  4. Sleep-disordered breathing, circulating exosomes, and insulin sensitivity in adipocytes

    International Journal of Obesity, Vol. 42, Núm. 6, pp. 1127-1139

2017

  1. Intuitive pharmacogenetic dosing of risperidone according to CYP2D6 phenotype extrapolated from genotype in a cohort of first episode psychosis patients

    European Neuropsychopharmacology, Vol. 27, Núm. 7, pp. 647-656

2016

  1. A Pharmacovigilance Study in First Episode of Psychosis: Psychopharmacological Interventions and Safety Profiles in the PEPs Project

    International Journal of Neuropsychopharmacology, Vol. 19, Núm. 4

  2. Pharmacogenetic study of antipsychotic induced acute extrapyramidal symptoms in a first episode psychosis cohort: Role of dopamine, serotonin and glutamate candidate genes

    Pharmacogenomics Journal, Vol. 16, Núm. 5, pp. 439-445